ADA Glycemic Targets: 2023 Recommendations

ADA Glycemic Targets Recommendations

ADA glycemic targets 2023 recommendations

The 2023 ADA Glycemic Targets Recommendations are summarized here. Achieving glycemic targets is important to delay or prevent diabetes-related complications.

The results of A1C, Fasting Blood Glucose, 2-hours post-prandial glucose, and continuous glucose monitor readings may differ especially in individuals with blood disorders, hemoglobinopathies, pregnancy, and individuals who are taking hematinics (supplements to improve anemia and red cell indices) [Ref].

Glycemic Assessment: ADA 2023 recommendations:
    • Assess glycemic status at least twice yearly in patients who meet glycemic targets and have a stable glycemic record.


    • Assess glycemic status every three months in patients who have unstable glycemic control, are not meeting glycemic targets, or whose therapy has been changed.

A1C to blood glucose chart:

The A1C-derived average glucose (ADAG) chart is presented here. The data is derived from a large-scale study.


Blood Glucose (mg/dl)

Blood Glucose (mmol/L)

5 97 5.4
6 126 7
7 154 8.6
8 183 10.2
9 212 11.8
10 240 13.4
11 269 14.9
12 298 16.5

Hypoglycemia and Hyperglycemia have been classified by the ADA as either level 1 or level 2. The table summarizes here the classification of hypoglycemia and hyperglycemia:

Degree of abnormal blood glucose

Level 2 hyperglycemia TAR: Percentage of readings and time > 250 mg/dl
Level 1 hyperglycemia TAR: Percentage of readings and time 181- 250 mg/dl
In-range blood glucose TAR: Percentage of readings and time 70 – 180 mg/dl
Level 1 hypoglycemia TAR: Percentage of readings and time 54 – 69 mg/dl
Level 2 hypoglycemia TAR: Percentage of readings and time < 54 mg/dl
You may also like to read:

ADA 2023 Glycemic Targets for Non-pregnant Diabetic Individuals:

The glycemic targets in non-pregnant diabetic individuals should be individualized based on multiple factors. These include:

  • Risk of hypoglycemia
  • Duration of diabetes
  • Life expectancy
  • Comorbid conditions
  • Established complications
  • Patient’s preferences
  • Resource and support system

Risk Factors

More stringent control

Less stringent control

Risks of hypoglycemia Low High
Disease duration Newly diagnosed diabetes Long-standing diabetes
Life expectancy Long Short
Co-morbid conditions Absent Severe
Vascular complications Absent Severe
Patient’s preferences Highly motivated Less motivated
Resources and support Readily available Limited

The A1C ADA Target recommendations:

ADA Glycemic Target Recommendations

A1C goal

The A1C goal for most non-pregnant diabetic individuals <7% without significant hypoglycemia
Ambulatory blood glucose and continuous glucose range For most individuals:

Time Blood glucose in the range: >70%

Time below range: <4%

Time <54 mg/dl: <1%

For elderly frail individuals:

Time Blood glucose in the range: >50%

Time below range: <1%

Strict control may be acceptable if the patient and the healthcare professional agree < 7%
Patients with limited life expectancy and risk of hypoglycemia <8% (64 mmol/mol)

Pharmacologic therapies and lifestyle interventions are intensified if a diabetic individual does not meet the targets.

Other than the A1C, pre-meals, and peak post-meal blood glucose as measured by a glucometer or continuous glucose monitor should be optimized.

A summary of the ADA 2023 recommendations is given in the table below:

Summary of glycemic recommendations for most non-pregnant adults with diabetes

A1C <7% (53 mmol/mol)
Premeals capillary plasma glucose 80 – 130 mg/dl (4.4 – 7.2 mmol/L)
Peak post-meal capillary plasma glucose <180 mg/dl (10 mmol/L)
You may also like to read:

Management of Hypoglycemia: ADA 2023 recommendations:

Hypoglycemia is a complication of most diabetes drugs. Novel antidiabetic drugs are usually not associated with hypoglycemia.

Diabetes drugs that are associated with hypoglycemia are:

Drugs that are associated with hypoglycemia

Drugs that are not associated with hypoglycemia

  • Sulfonylurea:
    • Glimepiride,
    • Gliclazide,
    • Glyburide
  • Meglitinides:
    • Repaglinide,
    • Nateglinide
  • Insulin:
    • Rapid-acting Insulin:
      • Glulisine
      • Aspart
      • Lispro
    • Short-acting Insulin:
      • Regular Insulin
    • Intermediate-acting Insulin:
      • NPH insulin
    • Long-acting Insulin:


You may also like to read:

Hypoglycemia: ADA 2023 recommendations:

Evaluate for the risk of hypoglycemia at every visit using validated tools

If the patient develops hypoglycemia:

  • 15 to 20 gm glucose per oral is the preferred treatment if the blood glucose is < 70 mg/dl.
  • The treatment may be repeated if hypoglycemia persists after 15 minutes of oral glucose intake.
  • The individual should consume a snack or take a regular meal once hypoglycemia improves.

If hypoglycemia is severe (level 2 or level 3 hypoglycemia), glucagon should be administered. Glucagon can be administered by care providers, teachers, parents, or anyone at home. Its use is not limited to healthcare providers.

In patients with one or more episodes of hypoglycemia unawareness should prompt the physicians to raise the target blood glucose for that individual.

In addition, the cause of hypoglycemia should be investigated in all patients.

Classification of Hypoglycemia

Level 1 hypoglycemia Blood glucose between 54 – 69 mg/dl (3 – 3.9 mmol/L)
Level 2 hypoglycemia  Blood Glucose < 54 mg/dl (3 mmol/L)
Level 3 hypoglycemia Severely symptomatic hypoglycemia when the patient needs assistance to correct hypoglycemia
You may also like to read:

What do you think?

Written by Dr. Ahmed

Dr. Ahmed is an experienced Internist with over fifteen years of practice in the medical field. He strongly believes that true medical practice is about helping people, not just prescribing pills.
He has found that the best results come from motivating patients to make small lifestyle changes in addition to prescribing medications when necessary.
With a focus on managing obesity, diabetes, hypertension, asthma, depression, arthritis, migraine, high cholesterol levels, and many more medical conditions in his patients, he shares his knowledge and expertise through writing health-related articles for
He is committed to helping patients achieve optimal health outcomes and improve their quality of life. For direct contact, he can be reached at

tysabri (Natalizumab) uses dose moa brands side effects

Tysabri (Natalizumab): Uses, Dose, MOA, Brands, Side effects

classification of diabetes ADA 2023 guidelines

Classification of Diabetes: ADA 2023 Updates